ASTRAZENECA PLC

AZN

Held by 3 specialist biotech funds

High Convergence

3 funds opened new positions. Next phase3 readout (Anastozole (Arimidex)): Jun 2001. Short interest: 0.2% of float.

Drug Manufacturers - GeneralCEO: Pascal Claude Roland SoriotIPO: 1993Website ↗

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Catalysts

Phase 3PositiveQ2 2001Anastozole (Arimidex)Breast CancerNCT00849030

Primary: Time to recurrence of breast cancer (Earliest of local or distant recurrence, new primary breast cancer, or death)Enrollment:9,358/9,358RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2002CiclesonideAsthmaNCT00546520

Primary: PC20FEV1 (AMP)Enrollment:21/21Sites: 1RANDOMIZED, DOUBLE, PREVENTION

Phase 3PositiveQ3 2002EsomeprazoleNSAIDs, Upper GI SymptomsNCT00241527

Primary: Mean change in the upper GI symptoms (pain, discomfort orEnrollment:Target 556Sites: 130RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2002EsomeprazoleNSAID Associated Gastric UlcersNCT00629512

Primary: To assess the efficacy of esomeprazole 40 mg qd versus placebo and esomeprazole 20 mg qd versus placebo for up to 6 months of the treatment for the prevention of gastric (and/or duodenal) ulcers in patients receiving daily NSAID therapy and being at risk (Assessments at Week 0, Week 4, Week 12, Week 26)Enrollment:Target 504RANDOMIZED, DOUBLE, PREVENTION

Phase 3Q4 2002RosuvastatinMyocardial Ischaemia, Coronary Artery DiseaseNCT00657527

Primary: Number of episodes of myocardial ischaemia as assessed by ambulatory electrocardiographic monitoring. (8 weekly)Enrollment:Target 280RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2003EsomeprazoleGERDNCT00241514

Primary: To assess the efficacy of esomeprazole 40 mg orally q.d. versus placebo orally q.d.Enrollment:Target 334Sites: 113RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2003budesonide/formoterolStable AsthmaNCT00658255

Primary: Average FEV1 during 12 hours (Once a week for 5 weeks during treatment period)Enrollment:Target 175RANDOMIZED, TREATMENT

Phase 3Q2 2003ZolmitriptanMigraineNCT00617747

Primary: Improvement in migraine headache pain from severe or moderate to mild or none (15 minutes after the initial dose of trial treatment)Enrollment:2,114/2,114RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2003budesonide/formoterolAsthmaNCT00651547

Primary: Morning PEF (Daily)Enrollment:Target 405RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2004RosuvastatinHypercholesterolemiaNCT00379249

Primary: Cumulative direct/indirect disease-related costs were compared applying a societal perspectiveEnrollment:Target 8,000RANDOMIZED, TREATMENT

Phase 2Q2 2004SaxagliptinType 2 Diabetes MellitusNCT00950599

Primary: Analysis of Test for Positive Efficacy Trend in Change From Baseline in Hemoglobin A1c (A1C) at Week 12 in the 0-40 mg Cohort (Baseline, Week 12)Enrollment:423/423RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ2 2004EXANTAStroke Prevention in Patients With Atrial FibrillationNCT00206063

Primary: Number of Adverse Events, with special regard to bleeding, thromboembolic events and discontinuation of treatment.Enrollment:Target 220Sites: 19RANDOMIZED, PREVENTION

Phase 3Q3 2004budesonideAsthmaNCT00642161

Primary: Change from Baseline in % predicted Forced Expiratory Volume in 1 second (Week 2, 4 and 8, then at week 12)Enrollment:Target 430RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2004RosuvastatinMetabolic Syndrome, DyslipidemiaNCT00240266

Primary: Determine the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.Enrollment:Target 15Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2004CiclesonideRhinitis, Allergic, Seasonal, Hay FeverNCT00659841

Primary: Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the first two weeks of treatment (4 weeks)Enrollment:302/302Sites: 6RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2005EsomeprazoleGastrointestinal Disease, Signs and Symptoms, Digestive, DyspepsiaNCT00251992

Primary: The primary outcome is whether the patient is a responder or not after 8 weeks treatment.Enrollment:Target 1,200Sites: 183RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2005budesonide/formoterol, 2x 200/6 microgram. 4 times dailyChronic Obstructive Pulmonary DiseaseNCT00239278

Primary: Eosinophils in induced sputum (as % of Total Cell Count), change from the start of the exacerbation to the end of 14 days treatmentEnrollment:Target 120Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2005budesonide/formoterol (Symbicort)Mild or Moderate AsthmaNCT00646516

Primary: Change from start of treatment in evening pre-dose FEV1 (2, 6 and 12 weeks after starting treatment)Enrollment:Target 615RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2005RosuvastatinHypercholesterolaemiaNCT00654303

Primary: Safety, as determined by adverse events, laboratory data, physical examination and ECG. (12 weekly)Enrollment:Target 3,500NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2005Ciclesonide nasalRhinitis, Allergic, Perennial, Hay FeverNCT00658918

Primary: Spontaneous and elicited adverse events (AEs) (6 weeks)Enrollment:120/120Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2005Esomeprazole (Nexium)Gastroesophageal Reflux Disease (GERD)NCT00241501

Primary: To evaluate safety & how tolerable a once daily treatment with esomeprazole is in pediatric & adolescent patientsEnrollment:Target 140Sites: 40RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2005CiclesonideAsthmaNCT00163384

Primary: FEV1 absolute values.Enrollment:Target 240Sites: 19RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2005Esomeprazole magnesium (Nexium)Zollinger-Ellison SyndromeNCT00079833

Primary: To assess the gastric acid secretory rate at the final study visit.Enrollment:Target 25Sites: 8NON_RANDOMIZED, TREATMENT

Phase 3Q3 2005exenatide/insulin glargineType 2 Diabetes MellitusNCT00099619

Primary: Change in HbA1c (glycosylated hemoglobin) from the baseline of the first period (16-weeks of exenatide or insulin) to the end of each 16-week period. (Baseline, Week 16, Week 32)Enrollment:138/138Sites: 26RANDOMIZED, TREATMENT

Phase 3Q3 2005QuetiapinePsychotic DisordersNCT00254813

Primary: Proportion of patients with moderate and severe adverse eventsEnrollment:Target 150Sites: 7RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2005ZD4054 10 mgProstatic Neoplasms, Metastases, NeoplasmNCT00055471

Primary: Dose Limiting Toxicities (DLTs) (Baseline to Day 29.)Enrollment:22/22Sites: 2TREATMENT

Phase 3Q4 2005CiclesonideAsthmaNCT00163462

Primary: FEV1 absolute valuesEnrollment:Target 750Sites: 57RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2005AnastrazoleBreast CancerNCT00255463

Primary: To determine and compare changes in proliferation marker at 16 weeks in the treatment groupsEnrollment:Target 185Sites: 34RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2006IR (Immediate-Release) quetiapine fumarate (drug)SchizophreniaNCT00254787

Primary: Proportion of patients who discontinue the study treatment due to adverse events (AEs) during the first week (day 1 to day 7) of treatmentEnrollment:Target 30Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2006Budesonide/formoterol TurbuhalerAsthmaNCT00259792

Primary: Time to first severe asthma exacerbationEnrollment:Target 1,000Sites: 82RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2006NXY-059Intracerebral HemorrhageNCT00075959

Primary: Global disability on modified Rankin scale at 90 daysEnrollment:Target 600Sites: 64RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2006Rosuvastatin calciumHypercholesteremiaNCT00225589

Primary: Assess the effects of rosuvastatin treatment on the change in the mean maximum intima media thickness (IMT) of the 12 vessel segments: the near & far walls of the CCA, the carotid bulb & the ICAEnrollment:Target 840Sites: 57RANDOMIZED, DOUBLE

Phase 2NegativeQ2 2006GefitinibMetastatic Breast CancerNCT00319618

Primary: Objective tumour response (CR + PR) per RECIST criteriaEnrollment:Target 66Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2006Budesonide/formoterolAsthmaNCT00290264

Primary: Time to first severe asthma exacerbationEnrollment:Target 1,000Sites: 209RANDOMIZED, TREATMENT

Phase 3Q3 2006RoflumilastBronchial AsthmaNCT00242307

Primary: change in lung function parameters.Enrollment:450/450Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2006AC2592Congestive Heart FailureNCT00099580

Primary: To examine the safety and tolerability of AC2592 administered by continuous subcutaneous infusion in subjects with chronic congestive heart failure. (6 weeks)Enrollment:61/61Sites: 29RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ3 2006NXY-059Cerebral Stroke, Stroke, Acute, Cerebrovascular StrokeNCT00061022

Primary: Global disability on modified Rankin scale at 90 days.Enrollment:Target 3,200Sites: 256RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ3 2006RoflumilastChronic Obstructive Pulmonary Disease (COPD)NCT00242294

Primary: change in lung function parameters (post-bronchodilator).Enrollment:Target 570Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ4 2006GalidaDiabetes Mellitus, Type 2NCT00214565

Primary: Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)Enrollment:Target 1,450Sites: 74RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2006quetiapine fumarateBipolar I DisorderNCT00107731

Primary: Evaluate the efficacy of quetiapine versus placebo when used as adjunct therapy to mood stabilizer in increasing time to recurrence of a mood event.Enrollment:Target 710Sites: 166RANDOMIZED, DOUBLE, PREVENTION

Phase 3PositiveQ4 2006Saxagliptin + MetforminDiabetes Mellitus, Type 2NCT00121667

Primary: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24)Enrollment:1,462/1,462Sites: 152RANDOMIZED, DOUBLE, TREATMENT

Phase 3NegativeQ4 2006TesaglitazarType 2 DiabetesNCT00255541

Primary: Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c)Enrollment:Target 580Sites: 66RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2006Anastrozole and goserelinBreast CancerNCT00235937

Primary: Determine the feasibility and efficacy of the combination of these 2 drugs in these patientsEnrollment:Target 45Sites: 7NON_RANDOMIZED, TREATMENT

Phase 3ApprovedQ1 2007Ciclesonide Nasal SprayRhinitis, Allergic, Seasonal, Hay FeverNCT00384475

Primary: Onset of action, measured by change from baseline in Total Nasal Symptom Score.Enrollment:Target 500Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2007RoflumilastChronic Obstructive Pulmonary Disease (COPD)NCT00246935

Primary: Long-term safety after 28 weeks treatment of Roflumilast (total 52 weeks, 24 weeks of study APTA-2217-06 followed by 28 weeks) .Enrollment:Target 150Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2007exenatideType 2 Diabetes MellitusNCT00324363

Primary: To test the hypothesis that exenatide (before morning and evening meals) produces a greater decrease in HbA1c than placebo in patients with type 2 diabetes and inadequate glycemic control taking metformin alone or metformin and sulfonylureas. (16 weeks)Enrollment:466/466Sites: 14RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2007RoflumilastCOPDNCT00242320

Primary: mean change from randomization to endpoint in lung function (post bronchodilator) (12 weeks)Enrollment:551/551Sites: 32RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2007BudesonideAsthmaNCT00259766

Primary: Asthma-related health-care utilization as measured by total amount of asthma medication purchased and number of contacts with health-care facilitiesEnrollment:Target 1,970Sites: 108RANDOMIZED, TREATMENT

Phase 2Q2 2007Ciclesonide HFARhinitis, Allergic, SeasonalNCT00807053

Primary: Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the first two weeks of treatment (2 weeks)Enrollment:480/480Sites: 31RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2007quetiapine fumarate tabletsSchizophreniaNCT00090324

Primary: Compare efficacy of Quetiapine with placebo in the treatment of schizophrenia as assessed by the PANSS total score, change from baseline to Day 42Enrollment:Target 249Sites: 42RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2007Quetiapine fumarate (Seroquel) SRAffective Psychosis, Bipolar, Manic Disorder, Manic-Depressive PsychosisNCT00422123

Primary: Change from baseline to final visit in the YMRS total scoreEnrollment:447/447Sites: 51RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2007exenatideType 2 DiabetesNCT00359879

Primary: Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12 (Baseline, Week 12)Enrollment:377/377Sites: 15RANDOMIZED, TREATMENT

Phase 3Q3 2007budesonide/formoterolChronic Obstructive Pulmonary DiseaseNCT00259779

Primary: Forced Expiratory Volume in one second (FEV1)Enrollment:Target 120Sites: 37RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2007Candesartan cilexetilHypertensionNCT00383929

Primary: Change (reduction) in sitting BP (24 hours after dose) (Assessed from baseline (randomisation) to the end of the study.)Enrollment:1,979/1,979Sites: 132RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2007AZD6244MelanomaNCT00338130

Primary: To compare the efficacy of AZD6244 vs temozolomide in patients with unresectable AJCC stage 3 or 4 malignant melanoma by assessing progression free survival (PFS) (From date of randomisation until 6 months after first dose or study withdrawal (whichever is the earliest))Enrollment:239/239Sites: 33RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2007Budesonide/formoterol pMDIChronic Obstructive Pulmonary DiseaseNCT00206167

Primary: Pre-dose and 1-hour post-dose FEV1 over the 12 months treatment periodEnrollment:Target 1,600Sites: 216RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2007SaxagliptinDiabetesNCT00316082

Primary: Change From Baseline in Hemoglobin A1 (A1C) at Week 24 (Baseline, Week 24)Enrollment:365/365Sites: 74RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2008CediranibCancerNCT00306891

Primary: Part A: Area Under Plasma Concentration-time Curve (AUC) (Measurements were collected up to 168 hours (following single dosing).)Enrollment:60/60Sites: 4RANDOMIZED, TREATMENT

Phase 3Q1 2008ABT-335 and rosuvastatin calciumHypercholesterolemia, DyslipidemiaNCT00463606

Primary: Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set) (Baseline to 12 Weeks)Enrollment:760/760Sites: 168RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2008exenatideType 2 Diabetes MellitusNCT00375492

Primary: Change From Baseline in Body Weight (Baseline, Week 24)Enrollment:196/196Sites: 10RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2008exenatideType 2 DiabetesNCT00360334

Primary: Percent of Patients Who Achieved HbA1c ≤ 7.4% With Minimal Weight Gain (≤ 1kg) (26 weeks)Enrollment:235/235Sites: 31RANDOMIZED, TREATMENT

Phase 2Q2 2008CP-675,206Carcinoma, Non-small-cell LungNCT00312975

Primary: The length of time until there is evidence of disease progression in patients treated with CP-675,206 and in patients receiving best supportive care. (3 months to 2 years from randomization)Enrollment:90/90Sites: 26RANDOMIZED, TREATMENT

Phase 3Q2 2008Symbicort TurbuhalerBronchial AsthmaNCT00536731

Primary: Morning Peak Expiratory Flow (PEF) (Baseline to 6 weeks)Enrollment:742/742Sites: 48RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2008GefitinibCarcinoma, Non-Small-Cell LungNCT00264498

Primary: Progression Free Survival (PFS) (Date of randomization to earliest date of objective disease progression)Enrollment:38/38Sites: 1RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2008exenatideDiabetes Mellitus, Type 2NCT00135330

Primary: Change in ASIiAUC During a Hyperglycemic Clamp Test. (20 weeks)Enrollment:137/137Sites: 19RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2008exenatide, long acting releaseType 2 Diabetes MellitusNCT00308139

Primary: Change in HbA1c From Baseline to Week 30 (Day -3, Week 30)Enrollment:303/303Sites: 25RANDOMIZED, TREATMENT

Phase 3Q3 2008CiclesonideAsthmaNCT00306163

Primary: PC20 AMP (Post-treatment Compared to Baseline) (Baseline and 5 weeks)Enrollment:37/37Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ3 2008AZD3480Alzheimer DiseaseNCT00501111

Primary: Change in ADAS-Cog (assessed after 12 weeks treatment)Enrollment:659/659Sites: 70RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2008BicalutamideNon-Metastatic Prostate CancerNCT00672282

Primary: Survival (Throughout study period)Enrollment:1,218/1,218Sites: 54RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2008AZD9668Chronic Obstructive Pulmonary Disease (COPD)NCT00703391

Primary: Alanine Aminotransferase (ALT) (Throughout the duration of the study (pre-dose, cmax, steady state, end of dosing and post dose))Enrollment:18/18Sites: 1RANDOMIZED, QUADRUPLE, BASIC_SCIENCE

Phase 3PositiveQ4 2008Aclidinium BromidePulmonary Disease, Chronic ObstructiveNCT00500318

Primary: Change From Baseline in Exercise Endurance Time (ET) (From baseline Week 0 (Visit 4) to Week 6 (Visit 6))Enrollment:181/181Sites: 52RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2009FulvestrantBreast CancerNCT00099437

Primary: Time to Progression (TTP) (RECIST(Response Evaluation Criteria in Solid Tumors ) tumour assessments carried out every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months))Enrollment:736/736Sites: 106RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2009exenatide once weeklyType 2 Diabetes MellitusNCT00637273

Primary: Change in HbA1c From Baseline to Week 26 (Day 1, Week 26)Enrollment:514/514Sites: 62RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2009RosuvastatinDiabetes MellitusNCT00296374

Primary: Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. (Assessed at Week 52, Last observation carried forward (LOCF))Enrollment:353/353Sites: 116RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2009saxagliptinType 2 DiabetesNCT00666458

Primary: Hemoglobin A1c (HbA1c) Change From Baseline to Week 18 (Baseline, Week 18)Enrollment:822/822Sites: 87RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2009Formoterol Turbuhaler® 4.5mgChronic Obstructive Pulmonary DiseaseNCT00628862

Primary: Forced Expiratory Volume in 1 Second (FEV1; L) 60 Minutes Post-dose (from baseline up to 12 weeks)Enrollment:613/613Sites: 47RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2009AZD5672Rheumatoid ArthritisNCT00713544

Primary: American College of Rheumatology 20 Response (ACR20) (12 weeks)Enrollment:373/373Sites: 49RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ2 2009AZD9668BronchiectasisNCT00769119

Primary: Ratio of Absolute Neutrophil Count at End of Treatment Compared to Baseline (End of treatment values from 3 visits (day 21 to 28) and baseline values from 3 visits.)Enrollment:38/38Sites: 9RANDOMIZED, QUADRUPLE, BASIC_SCIENCE

Phase 3Q2 2009CiclesonideAsthmaNCT00163293

Primary: Time to First Asthma Exacerbation (Up to 12 months)Enrollment:240/240Sites: 7RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ2 2009RosuvastatinHyperlipidemiaNCT00296400

Primary: Urinary Protein/Creatinine Ratio at Week 52 [LOCF] (Assessed at baseline and Week 52 (LOCF))Enrollment:237/237Sites: 107RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2009exenatide twice daily (BID)Type 2 Diabetes MellitusNCT00434954

Primary: Change in Glycosylated Hemoglobin (HbA1c) (Baseline and 26 weeks)Enrollment:494/494Sites: 39RANDOMIZED, TREATMENT

Phase 2MixedQ3 2009AZD1656Type 2 DiabetesNCT00817778

Primary: Systolic Blood Pressure, Change From Baseline to End of Treatment (Baseline is pre-dose first day of dosing, end of treatment is the morning following the treatment period)Enrollment:27/27Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2NegativeQ3 2009AZD9773 (CytoFab)Severe SepsisNCT00615017

Primary: Change From Baseline in Creatinine Values (End of study (Day 28))Enrollment:70/70Sites: 26RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ3 2009exenatide once weeklyType 2 Diabetes MellitusNCT00894322

Primary: Area Under the Curve (AUC) for Single Dose of 10 mg Exenatide (Cohort 1) in Healthy Participants in the Pharmacokinetic Evaluable Population (Day 1, Week 12)Enrollment:65/65Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3Q3 2009BudesonideAsthmaNCT00855959

Primary: Morning Peak Expiratory Flow (mPEF) (6 weeks)Enrollment:108/108Sites: 6NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2009AZD9668Cystic FibrosisNCT00757848

Primary: Ratio of Sputum Absolute Neutrophil Count at End of Treatment Compared to Baseline (Baseline and Values from day 21 to 28)Enrollment:56/56Sites: 14RANDOMIZED, QUADRUPLE, BASIC_SCIENCE

Phase 3Q4 2009Quetiapine XRSchizophrenic DisordersNCT00600756

Primary: Responder Rate at Month 6 in the Per Protocol Population Using the Subjective Well-being Under Neuroleptics Scale, Short Version (SWN-K) Total Score (6 months)Enrollment:798/798Sites: 116RANDOMIZED, TREATMENT

Phase 2Q4 2009AZD2171Metastatic Colorectal CancerNCT00494221

Primary: Progression Free Survival (RECIST at Baseline, Weeks 6, 12, 18, 24 and then every 12 weeks until progression through to a cut-off date of 13th Oct 2009 (based on approx 105 progression events observed across the 3 groups))Enrollment:172/172Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2009dapagliflozinType 2 DiabetesNCT00680745

Primary: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24)Enrollment:597/597Sites: 66RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2009Budesonide/formoterol (SYMBICORT) pMDIAsthmaNCT00419952

Primary: Total Number of Asthma Exacerbations (52 Weeks)Enrollment:742/742Sites: 122RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2009Aclidinium bromideChronic Obstructive Pulmonary DiseaseNCT00891462

Primary: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) (Change from Baseline to 12 weeks)Enrollment:561/561Sites: 112RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2009FulvestrantPuberty, Precocious, Mc Cune-Albright SyndromeNCT00278915

Primary: Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline (Baseline (6 month pre-treatment observation period) through Month 12 treatment period)Enrollment:30/30Sites: 16NA, TREATMENT

Phase 3PositiveQ1 2010DapagliflozinType 2 DiabetesNCT00683878

Primary: Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF]) (From Baseline to Week 24)Enrollment:972/972Sites: 89RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ1 2010AZD2281Ovarian Carcinoma, Breast CancerNCT00679783

Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines (Each patient with measurable disease at baseline was assessed for Objective Response from the sequence of RECIST scan data up to data cut-off, 26 March 2010. RECIST scans were performed every 8 weeks (+/- 2 weeks) from randomization.)Enrollment:99/99Sites: 6NON_RANDOMIZED, TREATMENT

Phase 3Q2 2010Terbutaline Turbuhaler®AsthmaNCT01096017

Primary: FEV1 (Forced Expiratory Volume in 1 Second) Area Under Curve (AUC) 0-4 Hours After Drug Inhalation (At two visits during a maximum of 15 days. FEV1 timepoints: all time points t=5, 15, 30, 60, 120, 180 and 240 minutes.)Enrollment:24/24Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3Q3 2010Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)SchizophreniaNCT00882518

Primary: Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42 (Baseline and 6 weeks)Enrollment:388/388Sites: 11RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2010budesonideExercise Induced AsthmaNCT00989833

Primary: Percent Change in Maximum Post-exercise Forced Expiratory Volume in One Second (FEV1) Fall After 6 Weeks (Baseline and Visit 6)Enrollment:66/66Sites: 10RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2010AZD1446Adult ADHDNCT01012375

Primary: AZD1446 compared to placebo, improves ADHD core symptoms in adult non-users and users of nicotine products after 2 weeks of treatment as measured by the Conners' Adult ADHD Rating Scale-Investigator Rated (CAARS-INV) Total ADHD Symptoms score (18 item) (The CAARS-INV will be administered once at each of the following visits: Visit 1; Visit 2; Visits 3,4,5; Visit 7; Visits 8, 9, 10; Visit 12; and Visits 13, 14 and 15)Enrollment:135/135Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ4 2010AZD8848Allergic RhinitisNCT01185080

Primary: Mean of Reflective (10 Min) Total Nasal Symptom Score (TNSS) (During 1st day to 7th day of Allergen challenge period.)Enrollment:93/93Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2011ZD4054Prostate CancerNCT00626548

Primary: Overall Survival (From date of randomization until date of death, assessed up to 33 months)Enrollment:2,577/2,577Sites: 322RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2011ticagrelorStable Coronary Artery DiseaseNCT01118325

Primary: Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients (Week 4)Enrollment:146/146Sites: 13RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ1 2011AZD2423Chronic Obstructive Pulmonary Disease, Lung DiseaseNCT01215279

Primary: Number of Participants With Clinically Significant Changes in Laboratory Variables Other Than Monocytes (Day 1, 1 week, 2 weeks, 3 weeks, 4 weeks and 5 weeks (follow-up))Enrollment:63/63Sites: 6RANDOMIZED, TRIPLE, BASIC_SCIENCE

Phase 3PositiveQ2 2011DapagliflozinType 2 Diabetes Mellitus, Cardiovascular Disease, Inadequate Glycaemic ControlNCT01042977

Primary: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24)Enrollment:964/964Sites: 135RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ2 2011AZD2423Neuropathic PainNCT01201317

Primary: Change From Baseline to Days 24-28 in Numerical Rating Scale (NRS) Average Pain Score. (Baseline (mean of Day -5 to Day -1) to the mean of Day 24 to Day 28)Enrollment:134/134Sites: 20RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2011RosuvastatinCoronary AtherosclerosisNCT00620542

Primary: Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV) (End of study (Week 104))Enrollment:2,333/2,333Sites: 195RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2011fulvestrantProgression-free SurvivalNCT00944918

Primary: Progression-free survival (every 3 months during treatment and, at time of discontinuation from treatment)Enrollment:25/25Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ3 2011Pramlintide+MetreleptinObesityNCT01235741

Primary: Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population (Day 1 up to Month 6 Follow-Up)Enrollment:213/213Sites: 18RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ4 2011olaparibOvarian CancerNCT01081951

Primary: Progression Free Survival (PFS) (Radiologic scans performed at weeks 9 and 18 (+/-1 week) and every 12 weeks thereafter relative to the date of randomisation until the primary analysis (approximately 20 months))Enrollment:162/162Sites: 53RANDOMIZED, TREATMENT

Phase 3Q4 2011EsomeprazoleHeartburnNCT01370538

Primary: Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment (From randomisation to day 14)Enrollment:341/341Sites: 10RANDOMIZED, DOUBLE, TREATMENT

Phase 2NegativeQ4 2011AZD6244MelanomaNCT00936221

Primary: Overall Survival (From date of randomization until death, withdrawal of consent or the end of the study. The end of the study was defined as the date all AZD6244 patients had been followed for a minimum of 12 months, or the date of final analysis, whichever was later)Enrollment:385/385Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ4 2011AZD6765Treatment Resistant Major Depressive DisorderNCT00986479

Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. (60 minutes (min) prior to dosing (baseline); and 60 min, 80 min, 110 min, 230 min, 1 day, 2 days, 3 days and 7 days following dosing.)Enrollment:22/22Sites: 1RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 201180/2.25 μg Symbicort pMDIAsthmaNCT01136655

Primary: Average 12 Hour Forced Expiratory Volume in 1 Second (FEV1) (at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes postdose)Enrollment:54/54Sites: 34RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2012TC-5214Major Depressive DisorderNCT01197508

Primary: Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment. (Randomization (Week 8) to end of treatment (Week 16))Enrollment:696/696Sites: 87RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2012TC-5214Major Depressive Disorder, MDD, DepressionNCT01152554

Primary: Frequency of Patients Experiencing at Least One Adverse Event (AE) (Randomization (Week 0) to end of the follow-up period (Week 54))Enrollment:813/813Sites: 94RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2012AZD1981Asthma PatientsNCT01197794

Primary: Pre-bronchodilator FEV1 at the Clinic (Twelve week treatment period)Enrollment:1,144/1,144Sites: 105RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2012AZD3199AsthmaNCT01348139

Primary: Emax: Maximum Value of FEV1 for Every Treatment Visits (0-24 hrs)Enrollment:39/39Sites: 3RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ1 2012Aclidinium/formoterol 400/12μgChronic Obstructive Pulmonary Disease (COPD)NCT01551888

Primary: Area Under the Formoterol Plasma Concentration Versus Time Curve (AUC) Over Dosing Interval at Steady State (Day 1: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (5 min before PM dose) and 5 and 15 min post PM dose; Days 2-4: 0, 5 and 15 min post dose; Day 5: 0, 5, 15 and 30 min and 1, 1.5, 2, 3, 4, 6, 8, and 12 hours (post AM dose))Enrollment:24/24Sites: 1RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2012AZD8931Neoplasms, Breast Neoplasms, Breast CancerNCT00900627

Primary: Phase I: The Number of Dose Limiting Toxicities in AZD8931 in Combination With Weekly Paclitaxel (Weekly visits for routine safety monitoring from Day 1 to Day 28 for each participant)Enrollment:330/330Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2012Olive oil, 4gHypertriglyceridemia, Cardiovascular DiseaseNCT01408303

Primary: Serum Non-HDL Cholesterol (6 weeks)Enrollment:646/646Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2012exenatideType 2 Diabetes MellitusNCT00960661

Primary: Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 30 (Baseline, 30 weeks)Enrollment:1,036/1,036Sites: 95RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2012DapagliflozinType2 Diabetes, High Blood SugarNCT01294436

Primary: Proportion of Participants With Adverse Events (Long-term treatment up to 52 weeks)Enrollment:728/728Sites: 38NA, TREATMENT

Phase 2Q4 2012AZD2115COPDNCT01498081

Primary: Peak Forced Expiratory Volume in 1 second (FEV1) defined as the maximum FEV1 from the spirometry assessments (During the first 24 hours following administration)Enrollment:39/39Sites: 6RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2012NKTR-118Opioid-Induced Constipation (OIC)NCT01336205

Primary: Incidence of Patients Experiencing at Least One Adverse Event (AE) (Baseline (Week 0) to end of the follow-up period)Enrollment:844/844Sites: 169RANDOMIZED, TREATMENT

Phase 2Q4 2012ER tablet 25 mg AZD3241Parkinson's DiseaseNCT01527695

Primary: Change of binding [11C]PBR28 to translocator protein (TSPO) measured by Positron Emission Tomography (PET). (baseline, 2-4 weeks)Enrollment:24/24Sites: 3RANDOMIZED, DOUBLE, BASIC_SCIENCE

Phase 3PositiveQ1 2013DapagliflozinType 2 DiabetesNCT01137474

Primary: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12 (From Baseline to Week 12)Enrollment:2,996/2,996Sites: 329RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2013Aclidinium Bromide/Formoterol FumarateChronic Obstructive Pulmonary DiseaseNCT01437540

Primary: Percentage of Patients to Experience at Least One Treatment-emergent Adverse Event (TEAE) (Up to study Week 56 ± 3 days)Enrollment:590/590Sites: 137RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2013fostamatinibRheumatoid ArthritisNCT01197534

Primary: Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo (24 weeks)Enrollment:913/913Sites: 149RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2013BicalutamideProstate CancerNCT00846976

Primary: Safety profile of patients treated with a 200 mg daily dose of CASODEX (every three months)Enrollment:101/101Sites: 1NA, TREATMENT

Phase 3Q2 2013DapagliflozinType 2 DiabetesNCT01257412

Primary: change in glycosylated haemoglobin A1c (HbA1c). (From baseline to week 24)Enrollment:Target 375Sites: 15RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2013FostamatinibRheumatoid ArthritisNCT01640054

Primary: Percentage of Patients Who Had at Least 1 Adverse Event in Any Category (Entry in extension to study termination (variable duration; maximum 52 weeks))Enrollment:115/115Sites: 26NA, TREATMENT

Phase 3Q1 2014IntralipidSedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic PolypectomyNCT01961349

Primary: Achivement of Target Sedation (from scope-in to scope-out)Enrollment:279/279Sites: 3RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2014Gefitinib 250mgLung CancerNCT01530334

Primary: Objective Response Rate (every 6 weeks after the Start of Study Treatment until objective disease progression or time of data cut off (6 months after the last patient has started study treatment))Enrollment:61/61Sites: 24NA, TREATMENT

Phase 3PositiveQ3 2014Exenatide once weekly suspensionDiabetes Mellitus, Type 2NCT01652716

Primary: Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28 (Baseline to Week 28)Enrollment:377/377Sites: 58RANDOMIZED, TREATMENT

Phase 3Q3 2014CiclesonideBronchial AsthmaNCT01455194

Primary: Asthma Control Questionnaire (ACQ) Score at Baseline (Baseline)Enrollment:520/520Sites: 30RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2014CiclesonideSeasonal Allergic RhinitisNCT02155881

Primary: Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS) (Baseline and Week 1 up to Week 2 (entire treatment period))Enrollment:80/80Sites: 5RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2015GefitinibLung Cancer, Breast CancerNCT00357734

Primary: Number of Serious Adverse Events (SAEs) (Serious adverse events (SAEs) and non-serious AEs were collected from the start of study treatment until 30 days after the last dose of study treatment or 30 days after last visit (up to approximately 120 months))Enrollment:14/14Sites: 7NA, TREATMENT

Phase 3Q3 2015RoflumilastChronic Obstructive Pulmonary Disease (COPD)NCT02165826

Primary: Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason (Baseline to Week 12 (Main Period))Enrollment:1,323/1,323Sites: 2RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2016Selumetinib 75 mgLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVNCT01750281

Primary: Progression Free Survival (PFS) (Baseline and then every 6 weeks after randomization until objective disease progression, up to 29 months (at the time of the analysis))Enrollment:212/212Sites: 68RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2016BenralizumabAsthmaNCT02417961

Primary: Number and Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home (Week 12, Week 16, and Weeks 12 and 16)Enrollment:162/162Sites: 23NA, TREATMENT

Phase 3Q2 2016OlaparibGastric CancerNCT01924533

Primary: Overall Survival (Survival contact from the date of randomization and then every 8 weeks following objective disease progression and in the 7 days following OS Data Cut off (DCO); Time point(s) at which outcome measure is assessed up to 4 years)Enrollment:525/525Sites: 57RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2016Non-alcoholic Fatty Liver Disease (NAFLD, HypertriglyceridemiaNCT02354976

Primary: Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo) (Baseline and 12 weeks)Enrollment:78/78Sites: 4RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2016SelumetinibLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVNCT01933932

Primary: Progression-Free Survival (PFS) (Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI))Enrollment:510/510Sites: 197RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2016BenralizumabAsthmaNCT02075255

Primary: Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control (Week 28)Enrollment:220/220Sites: 87RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2016Olaparib 300mg tabletsPlatinum Sensitive, BRCA Mutated, Relapsed Ovarian CancerNCT01874353

Primary: Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria In Solid Tumours (RECIST 1.1) (Radiologic scans performed at baseline then every ~12 weeks up to 72 weeks, then every ~ 24 weeks thereafter until objective radiological disease progression. Assessed until 19 Sep 2016 DCO (16 Jan 2017 DCO for China Cohort); up to a maximum of 36 months.)Enrollment:327/327Sites: 126RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2016AZD3241Multiple System Atrophy, MSANCT02388295

Primary: Striatum Brain Region: Change From Baseline in Microglia Activation Via Positron Emission Tomography(PET) (Baseline (pre randomization) and Week 12)Enrollment:59/59Sites: 17RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2016SaxagliptinType 2 DiabetesNCT02284893

Primary: Mean Change in HbA1c (Baseline (randomization) to Week 26)Enrollment:461/461Sites: 79RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ3 2016MEDI4736Recurrent/Metastatic Squamous Cell Carcinoma of Head & NeckNCT02319044

Primary: Objective Response Rate at 6 Months (After 6 months)Enrollment:267/267Sites: 125RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2016Open-label AZD2014Squamous Non Small Cell Lung CancerNCT02403895

Primary: Percentage of Patients Who Have a Partial Response or Complete Response Through Measurement of Tumour Lesion Sizes (From first dose until disease progression (Approximately 3 months))Enrollment:11/11Sites: 7NA, TREATMENT

Phase 3PositiveQ2 2017AZD9291 80 mg/40 mg + placeboLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerNCT02296125

Primary: Median Progression Free Survival (PFS) (Months) (At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression)Enrollment:674/674Sites: 170RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2017TralokinumabAsthmaNCT02449473

Primary: Change From Baseline to Week 12, Expressed as a Ratio, in Number of Airway Submucosal Eosinophils (Baseline (Week 0) and Week 12)Enrollment:79/79Sites: 15RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2017DapagliflozinType 2 Diabetes Mellitus, Inadequate Glycaemic ControlNCT02681094

Primary: Change From Baseline in HbA1c at Week 24 (Baseline and week 24)Enrollment:905/905Sites: 110RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2017TralokinumabAsthmaNCT02281357

Primary: Percent Change From Baseline in the Final Daily, Average, OCS Dose at Week 40 While Not Losing Asthma Control. (Baseline (Week 0) and Week 40)Enrollment:140/140Sites: 51RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ1 2018Tralokinumab open-labelInadequately Controlled AsthmaNCT02902809

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Screening (Day -14) up to 14 weeks after end of treatment (Week 66).)Enrollment:28/28Sites: 3NA, TREATMENT

Phase 3Q2 2018Benralizumab Arm AModerate to Very Severe Chronic Obstructive Pulmonary DiseaseNCT02138916

Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL (From first IP to week 56)Enrollment:1,656/1,656Sites: 407RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2018Olaparib 300mg tabletsNewly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IVNCT01844986

Primary: Progression Free Survival (PFS) Using Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) (Radiologic scans performed at baseline then every 12 weeks up to 156 weeks, then every 24 weeks thereafter until objective radiological disease progression. DCO: 17 May 2018)Enrollment:450/450Sites: 177RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2018MEDI4736 in combination with nab-paclitaxel and gemcitabineMetastatic Pancreatic Ductal AdenocarcinomaNCT02583477

Primary: Number of Participants With Dose-Limiting Toxicities (DLT) (Cohort 1: From time of first dose of MEDI4736 on Day 1 up to Day 28 of Cycle 1 and Cohort 2: From time of first dose of AZD5069 and MEDI4736 on Day 1 up to Day 28 of Cycle 1 or until a participant experiences a DLT, whichever occurs first.)Enrollment:23/23Sites: 7NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2018BenralizumabAsthmaNCT02869438

Primary: Change From Baseline (Visit 4) to Day 28 (Visit 8), Day 56 (Visit 9), and Day 84 (Visit 10) in Pre-BD FEV1 (From first IP dose to Day 84)Enrollment:233/233Sites: 54RANDOMIZED, DOUBLE, OTHER

Phase 3PositiveQ3 2018MEDI4736Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHNNCT02369874

Primary: Overall Survival (OS) (September 2015 to September 2018 (36 months))Enrollment:736/736Sites: 168RANDOMIZED, TREATMENT

Phase 3NegativeQ4 2018LanabecestatAlzheimer´s DiseaseNCT02245737

Primary: Change From Baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) (Baseline, Week 104)Enrollment:2,218/2,218Sites: 254RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q4 2018MEDI4736 (Durvalumab)Non-Small-Cell Lung Carcinoma NSCLCNCT02453282

Primary: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).)Enrollment:1,118/1,118Sites: 196RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2019olaparibMetastatic Castration-resistant Prostate CancerNCT02987543

Primary: Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only (Tumor assessments every 8 weeks from randomisation until radiographic progression assessed by BICR (median duration of treatment of 7 and 4 months for Olaparib and Investigators Choice of NHA respectively).)Enrollment:387/387Sites: 204RANDOMIZED, TREATMENT

Phase 3PositiveQ3 2019Zirconium CyclosilicateHyperkalemiaNCT03172702

Primary: Number of Patients Who Experienced Adverse Events (AEs) in the MP (First MP dose up to 1 day (2 days for QOD regimen) after last MP dose.)Enrollment:150/150Sites: 42NA, SUPPORTIVE_CARE

Phase 3PositiveQ3 2019DapagliflozinChronic Heart Failure With Reduced Ejection Fraction (HFr EF)NCT03036124

Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. (Up to 27.8 months.)Enrollment:4,744/4,744Sites: 419RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2019SavolitinibCarcinoma, Carcinoma, Renal Cell, Kidney NeoplasmsNCT03091192

Primary: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (RECIST tumour assessments every 6 weeks from randomisation until disease progression as defined by Recist 1.1 and confirmed by BICR.)Enrollment:60/60Sites: 59RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2019cediranib and olaparibRecurrent Platinum Resistant Ovarian CancerNCT02889900

Primary: Mean Objective Response Rate (ORR) by Independent Central Review (ICR) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (From baseline to primary analysis DCO (8 months after last patient received their first dose of IPs). RECIST assessments were performed at baseline and every 8 weeks (+/- 1 week) after first doses of IPs until disease progression.)Enrollment:62/62Sites: 25NA, TREATMENT

Phase 3Q4 2019Chronic Obstructive Pulmonary Disease (COPD)NCT03836677

Primary: Specific Image-based Airway Volume (siVaw) (Baseline, Day 29)Enrollment:23/23Sites: 4RANDOMIZED, TRIPLE, TREATMENT

Phase 2MixedQ4 2019AZD9567Rheumatoid ArthritisNCT03368235

Primary: Least Square (LS) Mean Change From Baseline in 28 Joint Disease Activity Score Using C-Reactive Protein (DAS28-CRP) at Day 15 (Baseline (Day 1) and Day 15)Enrollment:21/21Sites: 5RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ1 2020DurvalumabSmall Cell Lung Carcinoma Extensive DiseaseNCT03043872

Primary: Overall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP (From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).)Enrollment:987/987Sites: 207RANDOMIZED, TREATMENT

Phase 3Q1 2020MEDI4736 (Durvalumab)Urothelial CancerNCT02516241

Primary: To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set (From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).)Enrollment:1,126/1,126Sites: 222RANDOMIZED, TREATMENT

Phase 3Q1 2020OlaparibBreast CancerNCT02032823

Primary: Invasive Disease Free Survival (IDFS) (From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months))Enrollment:1,837/1,837Sites: 698RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2020MEDI4736 (Durvalumab)Advanced Solid MalignanciesNCT03084471

Primary: Number of Participants With Adverse Events of Special Interest (AESIs) (From screening to safety follow up visit (90 days after last dose), up to approximately 3 years.)Enrollment:867/867Sites: 79NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2020DapagliflozinType 2 DiabetesNCT02725593

Primary: Adjusted Change From Baseline in Glycated Haemoglobin (HbA1c) at Week 24 (Baseline to Week 24)Enrollment:72/72Sites: 42RANDOMIZED, DOUBLE, TREATMENT

Phase 2PositiveQ2 2020AZD5718Coronary Artery DiseaseNCT03317002

Primary: Change From Baseline in Creatinine-normalized u-LTE4 at Week 4 (Baseline and 4 weeks)Enrollment:129/129Sites: 9RANDOMIZED, TRIPLE, TREATMENT

Phase 3NegativeQ3 2020TicagrelorSickle Cell DiseaseNCT03615924

Primary: Number of Vaso-Occlusive Crisis Events (From randomization (Day 0) up to end of study (EOS) visit or date of premature study discontinuation, up to approximately 20 months)Enrollment:193/193Sites: 55RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2020Durvalumab +TremelimumabNon Small Cell Lung Carcinoma NSCLCNCT02542293

Primary: Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).)Enrollment:953/953Sites: 210RANDOMIZED, TREATMENT

Phase 2Q4 2020DurvalumabUrinary Bladder NeoplasmsNCT03459846

Primary: Progression-free Survival (PFS) (Assessments performed at baseline and every 8 weeks from date of randomization until date of objective disease progression or death (by any cause in the absence of progression), assessed up to the data cut-off date (15 Oct 2020), up to a max. of 31 months)Enrollment:154/154Sites: 44RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2020Olaparib Continuous (28-Day cycle) 300 mg BD.Metastatic Triple Negative Breast CancerNCT03330847

Primary: Progression-free Survival Per Stratum (BICR) (Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months))Enrollment:273/273Sites: 141RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2020AcalabrutinibCOVID-19NCT04380688

Primary: Number of Participants With Adverse Events and Serious Adverse Events (Screening to 28 (+3) days after last dose of acalabrutinib (for acalabrutinib + BSC participants) or to 38 (+3) days after randomization (for BSC alone participants))Enrollment:62/62Sites: 31RANDOMIZED, TREATMENT

Phase 2Q4 2020OLAPARIBRelapsed Ovarian Cancer, BRCA Mutation, Platinum SensitivityNCT02983799

Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) (From first dose up until progression, or last evaluable assessment in the absence of progression (up to 36 months))Enrollment:272/272Sites: 47NA, TREATMENT

Phase 3Q4 2020AZD1222COVID-19NCT04540393

Primary: Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability]. (180 days)0Sites: 4NA, PREVENTION

Phase 3Q4 2020Chronic Obstructive Pulmonary Disease (COPD)NCT04078126

Primary: Peak Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Within 4 Hours Post-dose Following 1 Week of Treatment (baseline and 4 hours post dose after 1 week of treatment)Enrollment:35/35Sites: 4RANDOMIZED, TREATMENT

Phase 2Q1 2021DurvalumabNon-small Cell Lung Cancer NSCLCNCT03775486

Primary: Progression-free Survival (From randomization until date of objective radiological disease progression or death, or last evaluable assessment in the absence of progression, up to 18 months)Enrollment:401/401Sites: 68RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2021DurvalumabNon Small Cell Lung Cancer NSCLCNCT03164616

Primary: Progression-Free Survival (PFS); D + SoC Compared With SoC Alone (Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).)Enrollment:1,186/1,186Sites: 175RANDOMIZED, TREATMENT

Phase 3Q1 2021Biological: Experimental: TezepelumabSevere AsthmaNCT04048343

Primary: Number of Subjects With Adverse Events (From first dose of study drug until last study visit at Week 64)Enrollment:65/65Sites: 5NA, TREATMENT

Phase 3PositiveQ2 2021BenralizumabAsthmaNCT03557307

Primary: Patients Who Achieve 100% Reduction in Daily OCS Dose (Baseline to end of OCS reduction phase, an average of approximately 200 days (The duration of the OCS reduction phase may vary based on asthma exacerbations, asthma worsening, HPA integrity , or other safety issues altering the OCS titration schedule.))Enrollment:598/598Sites: 144NON_RANDOMIZED, TREATMENT

Phase 2Q2 2021AZD8601Heart FailureNCT03370887

Primary: Number of Subjects With Adverse Events (From baseline to end of follow up at 6 months)Enrollment:11/11Sites: 10RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2021olaparibMetastatic Castration-resistant Prostate CancerNCT03732820

Primary: Number of Participants With Radiological Progression Free Survival (rPFS) Event by Investigator Assessment (Assessed from date of randomisation to data cut off (DCO1): 30Jul2021 (Approx. 2 years 9 months))Enrollment:895/895Sites: 132RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2021DurvalumabBiliary Tract NeoplasmsNCT03875235

Primary: Overall Survival (OS) (From date of randomization until death due to any cause. Assessed up to maximum of approximately 27 months (from date of randomization to primary analysis data cut-off))Enrollment:810/810Sites: 126RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2021DurvalumabHepatocellular CarcinomaNCT03298451

Primary: Overall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg (From the date of randomization until death due to any cause, assessed up to the data cut-off date (27Aug2021, to a maximum of approximately 46 months).)Enrollment:1,324/1,324Sites: 160RANDOMIZED, TREATMENT

Phase 2Q3 2021OlaparibOvarian, Breast, SCLCNCT02734004

Primary: Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12 (RECIST performed at baseline, at 4 weeks after first dose of olaparib monotherapy and every 8 weeks +/-7 days thereafter. Assessed until DCO 14 Jun 2019.)Enrollment:264/264Sites: 47NON_RANDOMIZED, TREATMENT

Phase 2Q4 2021AZD4635Progressive Metastatic Castrate-Resistant Prostate CancerNCT04495179

Primary: Radiographic Progression Free Survival (rPFS) in Each Arm Separately to Determine the Efficacy of AZD4635 Plus Durvalumab and of AZD4635 Plus Durvalumab Plus Cabazitaxel in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) (From first dose to first documented progression or death from any cause (whichever comes first) (approximately 1 year))Enrollment:30/30Sites: 16NON_RANDOMIZED, TREATMENT

Phase 2Q4 2021VerinuradChronic Kidney DiseaseNCT03990363

Primary: Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM) (Baseline to 9 months (Visit 9); analysis at 6 months (Visit 8))Enrollment:861/861Sites: 165RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2022DapagliflozinHeart Failure With Preserved Ejection FractionNCT03619213

Phase 3Q2 2022AZD9291 80 mg/40 mgStage IB-IIIA Non-small Cell Lung CarcinomaNCT02511106

Primary: Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). (Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months))Enrollment:682/682Sites: 238RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2022MonalizumabSquamous Cell Carcinoma of the Head and NeckNCT04590963

Primary: Overall Survival (OS) in Human Papillomavirus (HPV)-Unrelated Analysis Set (Baseline (-28 to -1) through 17.5 months (maximum observed duration))Enrollment:370/370Sites: 127RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2022DurvalumabSmall-Cell Lung CancerNCT04745689

Primary: Maintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy] (Up to 12 months)Enrollment:31/31Sites: 12NON_RANDOMIZED, TREATMENT

Phase 2Q3 2022600 mg AZD7442 IVCoronavirus Disease 2019 (COVID-19)NCT05184062

Primary: Adverse Events of Special Interest (recorded from the time of signature of the ICF up to 245 days)Enrollment:272/272Sites: 14RANDOMIZED, TRIPLE, OTHER

Phase 2Q3 2022AZD9833Advanced ER-Positive HER2-Negative Breast CancerNCT04214288

Primary: Progression-free Survival (PFS) (From date of randomisation to date of objective disease progression (or last evaluable assessment in the absence of progression) or death (up to data cut-off of 29 months))Enrollment:240/240Sites: 85RANDOMIZED, TREATMENT

Phase 3Q4 2022Durvalumab (MEDI4736)Non Small Cell Lung Carcinoma NSCLCNCT03003962

Primary: Overall Survival (OS) (From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022])Enrollment:669/669Sites: 92RANDOMIZED, TREATMENT

Phase 3Q4 2022DurvalumabNon-Small Cell Lung CancerNCT03800134

Primary: Pathological Complete Response (pCR) in modified intent-to-treat (mITT) population (Up to approximately 15 weeks after randomization)Enrollment:825/825Sites: 231RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2022AZD7648Advanced MalignanciesNCT03907969

Phase 2PositiveQ4 2022DurvalumabNon-small Cell Lung Cancer (NSCLC)NCT03693300

Primary: Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs) (Up to 6 months)Enrollment:117/117Sites: 28NON_RANDOMIZED, TREATMENT

Phase 2Q4 2022Osimertinib + SavolitinibNon-Small Cell Lung CancerNCT04606771

Primary: Objective Response Rate (ORR) (Tumour assessments every 6 weeks from randomisation up to 24 weeks, then every 8 weeks until objective disease progression (maximum of approximately 25 months))Enrollment:30/30Sites: 21RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2022AcalabrutinibPhase I: Relapsed or Refractory B-cell Malignancies, Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma, Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaNCT03932331

Primary: Phase I: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From the first dose administration up to 30 days following the date of last dose of study treatment, approximately 25 months.)Enrollment:105/105Sites: 23NON_RANDOMIZED, TREATMENT

Phase 2Q1 2023Trastuzumab deruxtecanAdvanced Solid Tumors With HER2 Mutation, eg:Colorectal, Urothelial, Gastric, Hepatobiliary, Endometrial, Melanoma, Ovarian, Cervical, Salivary Gland, Pancreatic, BreastNCT04639219

Primary: Confirmed Overall Response Rate (ORR) as Per RECIST v1.1 Using Independent Central Review (ICR) (Tumor scans performed at screening,then every 6 weeks (q6w) +/- 1 week relative to date of first treatment administration until RECIST v1.1 objective PD, withdrawal of consent, or death by any cause, up to DCO date of 25 Jan 2023 (approximately 24 months))Enrollment:102/102Sites: 30NA, TREATMENT

Phase 2Q1 2023Durvalumab / Tremelimumab Combination TherapyPediatric Cancer, Solid Tumor Pediatric, Hematological MalignanciesNCT03837899

Primary: Dose-Finding Phase: Maximum Serum Concentration (Cmax) of Durvalumab (Pre-infusion and post-infusion on Cycle 1 Day 1, Cycle 1 Day 8, Cycle 1 Day 15, pre-infusion and post-infusion on Cycle 2 Day 1, pre-infusion and post-infusion in Cycle 3, 4, 6, 8, 10 and 12)Enrollment:50/50Sites: 19NON_RANDOMIZED, TREATMENT

Phase 3Q1 2023High CholesterolNCT04964544

Primary: Overall Correct Initial TASS Outcome, Worst Case Imputation, First Co-Primary Endpoint (Self-Selection Population) (Study day -30 to -1, at initial TASS assessment)Enrollment:1,196/1,196Sites: 1NA, TREATMENT

Phase 3Q2 2023OsimertinibNon-Small Cell Lung CancerNCT04035486

Primary: Adverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only) (From first dose date to 28 days following last dose, up to 45 months)Enrollment:587/587Sites: 153RANDOMIZED, TREATMENT

Phase 3Q2 2023FulvestrantLocally Advanced (Inoperable) or Metastatic Breast CancerNCT04305496

Primary: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.)Enrollment:818/818Sites: 215RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2023MEDI3506Diabetic Kidney DiseaseNCT04170543

Primary: Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population (From baseline to Day 169)Enrollment:609/609Sites: 97RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2023BenralizumabEosinophilic Granulomatous VasculitisNCT04157348

Primary: Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48 (Week 36 and Week 48)Enrollment:140/140Sites: 50RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2023HFA MDIAsthmaNCT05850494

Primary: Change From Baseline in Normalized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 15 Minutes (AUC0-15 Min) Post-dose (30 minutes prior to dosing and at 5, 15, and 30 minutes post-dose)Enrollment:52/52Sites: 4RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2023CapivasertibRelapsed or Refractory B-cell Non-Hodgkin LymphomaNCT05008055

Phase 3Q3 2023DurvalumabNon-Small Cell Lung CancerNCT03519971

Primary: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).)Enrollment:328/328Sites: 86RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2023DurvalumabHepatocellular CarcinomaNCT03778957

Primary: Progression Free Survival (PFS) for Arm B vs Arm C (Approximately 5 years)Enrollment:724/724Sites: 166RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2023AZD9977Heart Failure, Chronic Kidney DiseaseNCT04595370

Phase 2Q3 2023Trastuzumab deruxtecanHER2-mutant Non-Small Cell Lung CancerNCT05246514

Primary: ICR-assessed ORR (Objective Response Rate) (Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off))Enrollment:72/72Sites: 28NA, TREATMENT

Phase 2Q4 2023Datopotamab Deruxtecan (Dato-DXd)Carcinoma, Non-Small-Cell Lung, Triple Negative Breast CancerNCT05460273

Primary: Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR) (TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.)Enrollment:119/119Sites: 21NA, TREATMENT

Phase 2Q4 2023TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT04039113

Primary: Rate of Moderate or Severe COPD Exacerbations in Participants With Moderate to Very Severe COPD. (From randomisation up to Week 52)Enrollment:337/337Sites: 91RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2024AcalabrutinibUntreated Chronic Lymphocytic LeukemiaNCT04075292

Primary: Progression Free Survival (PFS) Assessed by BICR (Response evaluations performed every 12 weeks from Cycle 4 Day 1 to Cycle 25, then every 24 weeks until PD or death, up to DCO date of 03 January 2024 (a maximum of approximately 47.5 months))Enrollment:155/155Sites: 46RANDOMIZED, TREATMENT

Phase 3Q1 2024Osimertinib 80mg/40mgNon Small Cell Lung Cancer (Stage III)NCT03521154

Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) (Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months)Enrollment:216/216Sites: 118RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2024DurvalumabSmall Cell Lung CancerNCT03703297

Primary: Durvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (Response evaluations performed every 8 weeks (q8w) ± 1 week up to 72 weeks, then every 12 weeks (q12w) ± 1 week up to 96 weeks, and then every 24 weeks (q24w) thereafter until PD, up to DCO date 15 January 2024 (a maximum of approximately 1936 days))Enrollment:730/730Sites: 183RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2024olaparibMetastatic Castration-resistant Prostate CancerNCT05171816

Primary: Radiological Progression Free Survival (rPFS) (Tumour imaging CT/MRI and bone scan were assessed every 8 weeks from randomisation to week 24 and then every 12 weeks until RECIST progression. Patients were followed up for 479 days (approx 16 months) at minimum and 913 days (approx 30 months) at maximum)Enrollment:110/110Sites: 26RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ1 2024Sodium Zirconium Cyclosilicate (SZC)Renal Insufficiency, Chronic, HyperkalemiaNCT05056727

Primary: Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69))Enrollment:1,112/1,112Sites: 276RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2024Trastuzumab DeruxtecanBreast CancerNCT04739761

Primary: Objective Response Rate (ORR) in Cohort 1 (Participants Without Brain Metastasis at Baseline) (From first dose (Day 1) to progression of disease (up to 2 years 7 months))Enrollment:506/506Sites: 81NA, TREATMENT

Phase 3Q1 2024Trastuzumab deruxtecanAdvanced or Metastatic Breast CancerNCT04494425

Primary: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months))Enrollment:866/866Sites: 293RANDOMIZED, TREATMENT

Phase 2Q2 2024CeralasertibMelanomaNCT05061134

Primary: Main Study: Objective Response Rate (ORR) (Cycle 1 Day 1 (Each Cycle is 28 days) until objective disease progression or the last evaluable assessment in the absence of progression, or data cut-off (1 year 8 months))Enrollment:194/194Sites: 66RANDOMIZED, TREATMENT

Phase 3Q2 2024DurvalumabMuscle Invasive Bladder CancerNCT03732677

Primary: Pathologic Complete Response (pCR) Rates at Time of Cystectomy (Up to 6 months)Enrollment:1,063/1,063Sites: 188RANDOMIZED, TREATMENT

Phase 3Q2 2024DurvalumabCarcinoma, Non-Small-Cell LungNCT03706690

Primary: Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set) (Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days))Enrollment:407/407Sites: 87RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2024Budesonide/albuterol metered-dose inhaler 160/180 μgAsthma, Exercise-InducedNCT06245551

Phase 3Q3 2024olaparibEndometrial NeoplasmsNCT04269200

Primary: Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments (At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months)Enrollment:805/805Sites: 201RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2024Dato-DXdBreast CancerNCT05104866

Primary: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months)Enrollment:732/732Sites: 167RANDOMIZED, TREATMENT

Phase 2Q3 2024CeralasertibAdvanced or Metastatic NSCLCNCT05941897

Primary: Objective response rate (ORR) (At month 6 after the last patient's first dose (approximately 18 months).)Enrollment:39/39Sites: 8NA, TREATMENT

Phase 3Q3 2024SelumetinibNeurofibromatosis 1, Plexiform Neurofibroma (PN)NCT04924608

Primary: Confirmed Partial and Complete Response Rate (ORR) by End of Cycle 16 Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) in Participants With NF1 Who Have Symptomatic, Inoperable PN. (From first dose up until progression (if it occurs prior to the end of Cycle 16), or the last evaluable assessment up to and including the end of Cycle 16, excluding MRI during prolonged study intervention interruption (defined as interruption >= 28 days))Enrollment:145/145Sites: 34RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2024osimertinibCarcinomaNCT03778229

Primary: Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set (Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.)Enrollment:367/367Sites: 90RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2024NirsevimabRespiratory Syncytial Virus InfectionsNCT06042049

Phase 2Q3 2024DurvalumabNon-Small Cell Lung CancerNCT03334617

Primary: Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) (Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years))Enrollment:528/528Sites: 45NON_RANDOMIZED, TREATMENT

Phase 2Q3 2024AZD0780DyslipidemiaNCT06173570

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 (From first day of treatment up to week 12)Enrollment:428/428Sites: 55RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2024CapivasertibHormone-Sensitive Prostate CancerNCT04493853

Primary: Radiographic Progression-free Survival (rPFS) (Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized)Enrollment:1,012/1,012Sites: 323RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2024AZD0171Locally Advanced or Metastatic Solid TumoursNCT04999969

Primary: Number of Participants With Adverse Events (AEs), Immune Mediated AEs (imAEs) and Serious AEs (SAEs) (From Cycle 1 Day 1 (each cycle was 28 days in length) until Day 90 (post last dose of study intervention), up to 34 months)Enrollment:126/126Sites: 34NA, TREATMENT

Phase 3Q4 2024OsimertinibNon-Small Cell Lung CancerNCT04351555

Primary: Major Pathological Response (MPR) - IASLC Method (From date of randomization to an average of 12 weeks after the first dose)Enrollment:358/358Sites: 158RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2024Osimertinib (AZD9291) pemetrexed cisplatin or carboplatinNon-small Cell Lung CancerNCT04765059

Primary: Progression Free Survival (PFS) (From date of first dose (Day 1) until date of progression at local site or death due to any cause or data cut-off date whichever occurred first (up to 3 years 1 month))Enrollment:98/98Sites: 40RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2024Neoadjuvant Olaparib monotherapy groupBreast CancerNCT05498155

Primary: To evaluate the efficacy, measured by pCR (pathological complete response) rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy, as assessed by central pathology review. (Approx. 4 to 6 months)Enrollment:50/50Sites: 37NON_RANDOMIZED, TREATMENT

Phase 2Q4 2024DurvalumabTriple Negative Breast NeoplasmsNCT03742102

Primary: Dose Limiting Toxicity (DLT) Events (From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8)))Enrollment:243/243Sites: 32RANDOMIZED, TREATMENT

Phase 2Q4 2024AZD7789Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction CancerNCT04931654

Primary: Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE) (From time of Informed Consent to 90 days post last dose of study intervention)Enrollment:136/136Sites: 21RANDOMIZED, TREATMENT

Phase 2ApprovedQ4 2024BaxdrostatUncontrolled HypertensionNCT06336356

Primary: Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test (Week 8)Enrollment:48/48Sites: 10RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2024DurvalumabGastrointestinal Neoplasms, Esophagogastric JunctionNCT04592913

Primary: Event-free survival (EFS) (Up to 5 years)Enrollment:957/957Sites: 156RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2025Trastuzumab deruxtecanMetastatic Breast CancerNCT04538742

Primary: Occurrence of adverse events (AEs)- Part 1 (Up to follow-up period, approximately 53 months)Enrollment:245/245Sites: 72RANDOMIZED, TREATMENT

Phase 2Q1 2025CeralasertibAdvanced Solid TumoursNCT04564027

Phase 2Q1 2025Administration of ceralasertibAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerNCT02264678

Primary: The number of subjects with adverse events/serious adverse events (From baseline until 28 days after discontinuation of study treatment for Module 1, 2 and 5 or until 90 days after discontinuation of study treatment for Module 3 and 4)Enrollment:358/358Sites: 28NON_RANDOMIZED, TREATMENT

Phase 3Q1 2025Trastuzumab DeruxtecanBreast Neoplasms, Breast Cancer, HER2-positive Early Breast CancerNCT05113251

Primary: Rate of Pathologic Complete Response (pCR). (Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025))Enrollment:927/927Sites: 145RANDOMIZED, TREATMENT

Phase 3Q1 2025BGF MDI 320/28.8/9.6 μgAsthmaNCT04609878

Primary: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24)Enrollment:2,274/2,274Sites: 360RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2025BevacizumabAdvanced Ovarian CancerNCT03737643

Primary: Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis Set (At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months)Enrollment:1,407/1,407Sites: 214RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2025DurvalumabHepatocellular CarcinomaNCT05557838

Primary: ≥Grade 3 Adverse Events and Adverse Events of Special Interest of Cohort 1 (From the time of signature of informed consent, throughout the treatment period, and up to the follow-up period, assessed up to 44months)Enrollment:214/214Sites: 29NON_RANDOMIZED, TREATMENT

Phase 3Q2 2025Durvalumab (MEDI4736)Non-muscle-invasive Bladder CancerNCT03528694

Primary: The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC (Up to 4 years)Enrollment:1,018/1,018Sites: 120RANDOMIZED, TREATMENT

Phase 2Q2 2025OsimertinibNon-Small Cell Lung CancerNCT03944772

Primary: Objective response rate (ORR) (Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average)Enrollment:247/247Sites: 47NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2025BenralizumabHypereosinophilic SyndromeNCT04191304

Primary: Time to First HES Worsening/Flare During the DB Treatment Period (DB period (Baseline to Week 24))Enrollment:134/134Sites: 52RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2025DurvalumabNon-Muscle- Invasive Bladder CancerNCT05943106

Primary: Incidence of Grade 3 or 4 Possibly related adverse events (PRAEs) (From the date of the first dose of study treatment (Day 1) until 6 months after the initiation of study treatment)Enrollment:100/100Sites: 19NA, TREATMENT

Phase 3Q2 2025savolitinibPapillary Renal Cell CarcinomaNCT05043090

Primary: Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib (Approximately 28 months post first subject randomized)Enrollment:148/148Sites: 137RANDOMIZED, TREATMENT

Phase 3Q2 2025AZD9833ER-Positive HER2-Negative Breast CancerNCT04964934

Primary: Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1) (From randomization until the earlier of the progression event or death (approximately 2 years))Enrollment:315/315Sites: 264RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2025AZD2693Nonalcoholic SteatohepatitisNCT05809934

Primary: Proportion of participants achieving NASH resolution without worsening of fibrosis based on histology after 52 weeks treatment (after 52 weeks)Enrollment:220/220Sites: 164RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3ApprovedQ3 2025BaxdrostatResistant HypertensionNCT06168409

Primary: Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy (Baseline to week 12)Enrollment:218/218Sites: 102RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2025Medi-546Systemic Lupus ErythematosusNCT04877691

Primary: British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response (At week 52)Enrollment:367/367Sites: 140RANDOMIZED, SINGLE, TREATMENT

Phase 3Q3 2025Dato-DXdBreast CancerNCT05374512

Primary: Progression Free Survival (PFS) (From randomization until progression as assessed by BICR or death due to any cause (anticipated to be up to 26 months))Enrollment:644/644Sites: 228RANDOMIZED, TREATMENT

Phase 3Q4 2025DurvalumabBiliary Tract CancerNCT05771480

Primary: Number of participants with Grade 3 or 4 possibly related adverse event (PRAE) (Within 6 months after the initiation of Investigational Medicinal Product (IMP))Enrollment:142/142Sites: 34NA, TREATMENT

Phase 3Q4 2025CeralasertibAdvanced or Metastatic Non-Small Cell Lung CancerNCT05450692

Primary: Overall Survival (OS) (Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years))Enrollment:594/594Sites: 191RANDOMIZED, TREATMENT

Phase 2Q4 2025Trastuzumab deruxtecanAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)NCT06271837

Primary: Confirmed Objective Response Rate (ORR) (An average of approximately 12 months)Enrollment:127/127Sites: 29NON_RANDOMIZED, TREATMENT

Phase 2Q4 2025AZD9829Hematological MalignanciesNCT06179511

Primary: Frequency of dose limiting toxicities (DLTs). (Module 1 - 28 days.)Enrollment:56/56Sites: 22NON_RANDOMIZED, TREATMENT

Phase 3Q4 2025BenralizumabSevere Eosinophilic AsthmaNCT06465485

Primary: To assess the potential for benralizumab treated patients to reduce their standard of care asthma controller regimen in the overall patient populationa and by subgroups of baseline background therapy (within 40 weeks after the first administration)Enrollment:504/504Sites: 74NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2025BaxdrostatUncontrolled Hypertension, Resistant HypertensionNCT06344104

Phase 2Q1 2026AtuliflaponAsthmaNCT05251259

Phase 2Q1 2026DurvalumabNon-small Cell Lung CancerNCT05925530

Primary: Resection rate (At day of surgery (Within 40 days of the last dose of neoadjuvant treatment))Enrollment:142/142Sites: 49NA, TREATMENT

Phase 3PositiveQ1 2026TozorakimabChronic Obstructive Pulmonary Disease (COPD)NCT05166889

Phase 3PositiveQ1 2026TozorakimabChronic Obstructive Pulmonary Disease (COPD)NCT05158387

Primary: Annualized rate of moderate to severe COPD exacerbations in participants who are former smokers. (over 52 weeks)Enrollment:1,172/1,172Sites: 212RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2026AZD4117Influenza ANCT07128615

Primary: Percentage of participants with immediate unsolicited adverse events (AE) (Within 30 minutes after dosing)Enrollment:405/405Sites: 14RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q1 2026TremelimumabHepatocellular CarcinomaNCT05301842

Primary: Progression Free Survival (PFS) for Arm A vs Arm C (Approximately 5 years)Enrollment:760/760Sites: 171RANDOMIZED, SINGLE, TREATMENT

Phase 2Q1 2026AZD3470Advanced Solid Tumors That Are MTAP DeficientNCT06130553

Primary: All Modules: Incidence of adverse events (AEs) and serious adverse events (SAEs). To determine the RP2D of AZD3470 as monotherapy and in combination with anticancer agents (From time of informed consent to 28 days post last dose of study treatment)Enrollment:Target 334Sites: 21NA, TREATMENT

Phase 3PositiveQ1 2026Chronic Obstructive Pulmonary Disease (COPD)NCT05742802

Phase 3Q1 2026BDA MDI HFO 160/180 μgAsthmaNCT06502366

Primary: Change from baseline in peak FEV1 in 0-60 minutes after dosing at Day 29 (Change from baseline at Day 29)Enrollment:424/424Sites: 128RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2026capivasertibProstate CancerNCT05348577

Primary: Overall Survival (OS) in the overall population (up to approximately 46 months)Enrollment:1,035/1,035Sites: 217RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2026Chronic Obstructive Pulmonary Disease (COPD)NCT06040086

Phase 3Q1 2026CapivasertibTriple Negative Breast NeoplasmsNCT03997123

Primary: Overall Survival (OS) (The time from date of randomisation to the date of death due to any cause up to approximately 42 months)Enrollment:923/923Sites: 260RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2026DurvalumabAdvanced Hepatocellular CarcinomaNCT05883644

Primary: Incidence of grade 3 or 4 possibly related to treatment adverse events (PRAEs) (From the date of first dose of IMP until 6 months after the initiation of study intervention)Enrollment:111/111Sites: 40NA, TREATMENT

Phase 3Q2 2026DurvalumabUnresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial CancerNCT03682068

Primary: Overall Survival (OS) (approximately 5 years)Enrollment:1,246/1,246Sites: 222RANDOMIZED, TREATMENT

Phase 3Q2 2026Trastuzumab DeruxtecanLocally Advanced or Metastatic Non-Small Cell Lung CancerNCT05048797

Primary: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (Until progression or death, assessed up to approximately 12 months)Enrollment:454/454Sites: 130RANDOMIZED, TREATMENT

Phase 2Q2 2026Chronic Obstructive Pulmonary Disease (COPD)NCT06897748

Primary: Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in Clinic (Baseline through Week 12)Enrollment:98/98Sites: 12RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2026DurvalumabMuscle Invasive Bladder CancerNCT04960709

Primary: To assess the safety and tolerability as evaluated by adverse events occurring throughout the study (Safety Run-In part) (At completion of study treatment by the last patient and at 3 months.)Enrollment:712/712Sites: 196RANDOMIZED, TREATMENT

Phase 2Q2 2026AZD7798Moderate to Severe Crohn's DiseaseNCT06450197

Primary: CDAI remission (Week 12)Enrollment:120/120Sites: 116RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2026AZD3470Lymphoma, Non-Hodgkin, Hodgkin LymphomaNCT06137144

Primary: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (From Screening continuously until 28 days after the last dose of study medication.)Enrollment:Target 161Sites: 39RANDOMIZED, TREATMENT

Phase 3Q2 2026EplontersenTransthyretin Amyloid CardiomyopathyNCT06194825

Primary: Percent change of serum TTR concentration from baseline (up to 24 weeks)Enrollment:64/64Sites: 26RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2026AZD0901Gastric Cancer, Gastroesophageal Junction CancerNCT06346392

Primary: Progression Free Survival (PFS) in all randomized participants (From date of first dose/randomisation until disease progression or death in the absence of progression (approximately 3 years).)Enrollment:594/594Sites: 158RANDOMIZED, SINGLE, TREATMENT

Phase 2Q2 2026AZD9550Obesity or OverweightNCT06862791

Phase 2Q2 2026AZD6234Endocrinology, Diabetes, Type II, ObesityNCT06851858

Primary: Percent change in body weight from baseline at Study Week 26 (From baseline to week 26)Enrollment:69/69Sites: 18RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q2 2026DurvalumabHepatocellular CarcinomaNCT03847428

Primary: Recurrence-free survival (RFS) for Arm A vs Arm C (Up to 49 months after first patient randomized)Enrollment:908/908Sites: 217RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2026DurvalumabEsophageal Squamous Cell CarcinomaNCT04550260

Primary: Progression free survival (PFS) per RECIST 1.1 as assessed by BICR (up to approximately 56 months)Enrollment:640/640Sites: 133RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2026SavolitinibCarcinoma, Non-Small-Cell LungNCT05261399

Primary: Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib. (Approximately 36.5 months post first subject randomized)Enrollment:341/341Sites: 214RANDOMIZED, TREATMENT

Phase 3Q2 2026TozorakimabViral Lung Infection and Acute Respiratory FailureNCT05624450

Primary: Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO) (by Day 28)Enrollment:Target 3,527Sites: 471RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q2 2026OleclumabNon-Small Cell Lung CancerNCT06606847

Primary: Progression free survival (PFS) at 12 months (From date of first dose until 12 months)Enrollment:30/30Sites: 11NA, TREATMENT

Phase 3Q2 2026DurvalumabNon-Small Cell Lung CancerNCT05221840

Primary: Progression Free Surival (PFS) (Up to 5 years after first patient randomized.)Enrollment:1,051/1,051Sites: 202RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026DurvalumabHepatocellular Carcinoma (HCC)NCT06040099

Primary: Progression Free Survival (PFS) (From Day 1 until date of progressive disease or death [Approximately 3 years])Enrollment:58/58Sites: 21NA, TREATMENT

Phase 3Q3 2026Trastuzumab deruxtecanBreast Cancer; HER2-positive; MetastaticNCT04784715

Primary: Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment (Until progression or death, assessed up to approximately 60 months)Enrollment:1,157/1,157Sites: 283RANDOMIZED, TREATMENT

Phase 2Q3 2026OsimertinibLung CancerNCT06194448

Primary: PFS (Progression-Free Survival) (Assessed from date of first dose to progression (up to a maximum of approximately 4 years))Enrollment:76/76Sites: 39NA, TREATMENT

Phase 3Q3 2026TezepelumabEosinophilic EsophagitisNCT05583227

Primary: Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels (Week 24)Enrollment:368/368Sites: 124RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2026OlaparibOvarian CancerNCT04884360

Primary: Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment. (Approximately 3 years)Enrollment:366/366Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026Zibotentan/DapagliflozinChronic Kidney Disease With High ProteinuriaNCT06942910

Primary: Change in log-transformed Urinary Albumin to Creatinine Ratio (UACR) from baseline (At Week 12)Enrollment:224/224Sites: 14RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2026AZD6234Obesity/OverweightNCT07017179

Primary: Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1). (From baseline to Day 141)Enrollment:16/16Sites: 3RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q3 2026DurvalumabNon-Small Cell Lung CancerNCT05211895

Primary: Progression Free Survival (PFS) (Up to 5 years after randomization)Enrollment:791/791Sites: 226RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026AZD0901Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract CancerNCT06219941

Primary: Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs. (30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.)Enrollment:Target 226Sites: 52RANDOMIZED, TREATMENT

Phase 3Q3 2026Nexium 20mgErosive EsophagitisNCT05267613

Primary: Presence / absence of Erosive Esophagitis (Week 24 (end of 16-week maintenance phase))Enrollment:53/53Sites: 41RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026AZD7798Crohn's DiseaseNCT06681324

Primary: Number of participants with adverse events (from Week 0 to Week 12)Enrollment:24/24Sites: 17RANDOMIZED, TRIPLE, OTHER

Phase 3Q3 2026AZD9833ER-Positive HER2-Negative Breast CancerNCT04711252

Primary: Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 (From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years))Enrollment:1,371/1,371Sites: 263RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q3 2026AZD2936Non-Small-Cell Lung CarcinomaNCT04995523

Primary: Percentage of participants with adverse events (AEs) and immune mediated AEs (imAEs), serious AEs (SAEs), dose limiting toxicities (DLTs), vital signs, and abnormal laboratory parameters (Part A, B, C, D and E: From the time of informed consent until 90 days after the last dose of rilvegostomig)Enrollment:212/212Sites: 40NON_RANDOMIZED, TREATMENT

Phase 2Q3 2026AZD0901Gastric Cancer, Gastroesophageal Junction CancerNCT07143604

Primary: Objective Response Rate (ORR) (At month 6 after date of first dose)Enrollment:33/33Sites: 13NA, TREATMENT

Phase 3Q3 2026Dato-DXdMetastatic Non-small Cell Lung CancerNCT06417814

Primary: Progression free Survival (PFS) (Up to 2.5 years)Enrollment:Target 744Sites: 303RANDOMIZED, TREATMENT

Phase 2Q3 2026DyslipidaemiaNCT07218900

Primary: Relative change in Low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeks (Baseline - 12 weeks)Enrollment:76/76Sites: 8RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2026VolrustomigHepatocellular Carcinoma, Biliary Tract CancerNCT05775159

Primary: Objective response rate (ORR) (Through study completion, an average of 2 years)Enrollment:Target 294Sites: 46NON_RANDOMIZED, TREATMENT

Phase 3Q4 2026AsthmaNCT06471257

Primary: Time to first severe asthma exacerbation (24 to 52 weeks)Enrollment:Target 1,000Sites: 102RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2026CapivasertibBreast CancerNCT06635447

Primary: Time to first subsequent treatment (TFST) of PIK3CA/AKT1/PTEN-altered population in Cohort 1 (From the first dose of study intervention to the earlier of start date of the first subsequent therapy after discontinuation of study intervention, or death in PIK3CA/AKT1/PTEN-altered population in Cohort 1, up to approximately 2 years)Enrollment:293/293Sites: 76NON_RANDOMIZED, TREATMENT

Phase 2Q4 2026AZD0754Metastatic Prostate CancerNCT06267729

Primary: Incidence of participants with Dose-limiting Toxicity (DLTs)/DLT-like events, Adverse Events (AEs), including Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs). (Through study completion, an average of 2 years)Enrollment:Target 60Sites: 15NON_RANDOMIZED, TREATMENT

Phase 2Q4 2026AZD7760Staphylococcus AureusNCT06749457

Primary: Phase I: Occurence of adverse events (AEs) (Day 1 to Day 181)Enrollment:244/244Sites: 40RANDOMIZED, QUADRUPLE, PREVENTION

Phase 2Q4 2026DurvalumabHepatocellular CarcinomaNCT07081633

Primary: Progression free survival (PFS) per RECIST 1.1 (From the date of first dose until the date of objective PD per RECIST 1.1 or death, whichever came first. It will be assessed when approximately 69 PFS events have occurred (60% maturity), approximately 8 months after the last patients dosed.)Enrollment:114/114Sites: 23NA, TREATMENT

Phase 2Q4 2026DurvalumabCarcinoma, Non-Small-Cell LungNCT06008093

Primary: Progression-free survival (PFS) in randomized participants (From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months))Enrollment:103/103Sites: 47RANDOMIZED, TREATMENT

Phase 3Q4 2026Cutaneous Lupus ErythematosusNCT06015737

Primary: Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score (At Week 24)Enrollment:339/339Sites: 188RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2026DurvalumabCancerNCT05303532

Primary: Number of participants with serious adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (From baseline up to follow up at 90 days after the last dose of study drug.)Enrollment:Target 214Sites: 123NA, TREATMENT

Phase 3Q1 2027AZD0780Heterozygous Familial HypercholesterolaemiaNCT07000136

Primary: Relative change in LDL-C from baseline to 12 weeks (Baseline - 12 weeks)Enrollment:473/473Sites: 133RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2027Systemic Sclerosis, SclerodermaNCT05925803

Primary: Number of participants responding to treatment based on the Revised Composite Response Index in Systemic Sclerosis (CRISS-25) (at Week 52)Enrollment:314/314Sites: 150RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2027AZD0780Cardiovascular DiseaseNCT07000123

Primary: Relative change in LDL-C from baseline to 12 weeks (Baseline - 12 weeks)Enrollment:3,103/3,103Sites: 404RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2027Chronic Rhinosinusitis With Nasal PolypsNCT06706817

Primary: Change from baseline in nasal congestion (Week 24)Enrollment:181/181Sites: 41NA, TREATMENT

Phase 2Q1 2027SavolitinibLung CancerNCT05374603

Primary: PFS (The analysis will occur when 60 percent PFS event is observed in each cohort, at approximately 10 months after last patient in.)Enrollment:47/47Sites: 16NA, TREATMENT

Phase 2Q1 2027AZD0901Gastroesophageal AdenocarcinomaNCT07069712

Primary: Number of participants with adverse events (AEs) and serious adverse events (SAEs) (Until sub-study completion, up to 38 months)Enrollment:Target 100Sites: 70NON_RANDOMIZED, TREATMENT

Phase 2Q1 2027AZD9550Overweight and ObesityNCT06151964

Primary: Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study. (Day - 35 to Day 261)Enrollment:166/166Sites: 15RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2027AZD4144Sepsis, Acute Kidney InjuryNCT07215702

Primary: Area Under the Curve (AUC) of 24-hour Creatinine Clearance (CrCl). (During the treatment period.)Enrollment:Target 124Sites: 74RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2027Zibotentan/DapagliflozinChronic Kidney Disease With High ProteinuriaNCT06087835

Primary: Change in eGFR from baseline (At month 24)Enrollment:1,835/1,835Sites: 296RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2027OsimertinibCancerNCT05629234

Primary: Number of patients with Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (Until 90 days after the last dose of study treatment)Enrollment:Target 37Sites: 27NA, TREATMENT

Phase 3Q1 2027DyslipidaemiaNCT06834932

Primary: AZD0780 Concentrations in plasma (PART A) (Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A))Enrollment:432/432Sites: 42RANDOMIZED, TRIPLE, TREATMENT

Phase 3Q1 2027AnifrolumabLupus NephritisNCT05138133

Primary: Difference in proportion of participants with CRR (Complete Renal Response) in anifrolumab group compared with placebo group (Week 52)Enrollment:363/363Sites: 164RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2027SurovatamigB-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)NCT06526793

Primary: Overall response rate (ORR) (central review) (Module 1: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 24 months. Module 2: from first dose to end of treatment or data cutoff, whichever comes first, assessed up to approximately 12 months.)Enrollment:Target 270Sites: 94NON_RANDOMIZED, TREATMENT

Phase 2Q1 2027Trastuzumab deruxtecanPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerNCT04482309

Primary: Objective Response Rate (ORR) (An average of approximately 6 months)Enrollment:477/477Sites: 89NON_RANDOMIZED, TREATMENT

Phase 2Q1 2027AZD4360Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract CancerNCT06921928

Primary: Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360 (Through study completion, up to approximately 2 years)Enrollment:31/31Sites: 14NA, TREATMENT

Phase 3Q2 2027OlaparibOvarian Cancer, Breast CancerNCT04421963

Primary: Safety follow up (Baseline up to approximately 10 years)Enrollment:185/185Sites: 107NA, TREATMENT

Phase 3Q2 2027CamizestrantBreast Cancer, Early Breast CancerNCT05774951

Primary: Invasive breast cancer-free survival (IBCFS) (Up to 10 years)Enrollment:Target 4,300Sites: 709RANDOMIZED, TREATMENT

Phase 2Q2 2027AZD5148Clostridioides Difficile InfectionNCT07285213

Primary: First occurrence of recurrence of C difficile infection (Day 1 through day 91)Enrollment:Target 230Sites: 117RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3Q2 2027Polymyositis, DermatomyositisNCT06455449

Phase 2Q2 2027Baxdrostat/dapagliflozinChronic Kidney Disease and HypertensionNCT07222917

Phase 2Q2 2027AZD5305Ovarian Cancer, Breast Cancer, Pancreatic CancerNCT04644068

Phase 3Q2 2027Placebo to match laroprovstat/rosuvastatin 1,2,3HypercholesterolaemiaNCT07619118

Phase 2Q2 2027VolrustomigMetastatic Colorectal CancerNCT06792695

Phase 2Q2 2027Fluorouracil (5-FU)Gastric CancerNCT04379596

Phase 3Q2 2027balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mgHeart Failure and Impaired Kidney FunctionNCT06307652

Phase 2Q2 2027Acalabrutinib + R-CHOP standard of careMantle-cell LymphomaNCT07029737

Phase 2Q2 2027TozorakimabAsthmaNCT06932263

Phase 3Q2 2027Severe AsthmaNCT06473779

Phase 2Q2 2027AZD9793 Intravenous (IV) monotherapyHepatocellular CarcinomaNCT06795022

Phase 3Q2 2027Datopotamab DeruxtecanNon-small Cell Lung CancerNCT06564844

Phase 2Q3 2027AZD2389Liver Fibrosis, Hepatic CirrhosisNCT07610837

Phase 3Q3 2027AcalabrutinibChronic Lymphocytic Leukemia or Small Lymphocytic LymphomaNCT05057494

Phase 2Q3 2027AZD5863Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal AdenocarcinomaNCT06005493

Phase 3Q3 2027Dato-DXdBreast CancerNCT06103864

Phase 2Q3 2027VolrustomigNon-small Cell Lung CancerNCT06448754

Phase 3Q3 2027LaroprovstatHypercholesterolaemiaNCT07619131

Phase 3Q3 2027OsimertinibNon-Small Cell Lung CancerNCT05120349

Phase 2Q3 2027AZD8421ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)NCT06188520

Phase 3Q3 2027TezepelumabSevere AsthmaNCT07363642

Phase 3Q3 2027BaxdrostatPrimary HyperaldosteronismNCT07007793

Primary: Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8 (At week 8)Enrollment:Target 250Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2027AZD0305Multiple MyelomaNCT06106945

Phase 2Q3 2027APOL1-Mediated Kidney DiseaseNCT06824987

Phase 2Q3 2027AZD0120Relapsed/Refractory Multiple MyelomaNCT05850234

Phase 3Q3 2027Dato-DXdBreast CancerNCT05629585

Phase 2Q3 2027AZD8205Breast Cancer, Biliary Tract Carcinoma, Ovarian CancerNCT05123482

Phase 2Q4 2027OsimertinibNon-Small Cell Lung Cancer (NSCLC)NCT05801029

Phase 2Q4 2027Datopotamab deruxtecan (Dato-DXd)Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate CancerNCT05489211

Phase 3Q4 2027AsthmaNCT06307665

Primary: Annualized rate of severe asthma exacerbations (AAER) (From Randomization (Day 1) to Week 52 (EOT))Enrollment:Target 440Sites: 150RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2027Puxitatug SamrotecanEndometrial Cancer, Malignant Solid TumourNCT07044336

Phase 3Q4 2027Datopotamab deruxtecanNSCLCNCT05687266

Phase 3Q4 2027CapivasertibLocally Advanced (Inoperable) or Metastatic Breast CancerNCT04862663

Phase 3Q4 2027Eosinophilic AsthmaNCT06750289

Primary: Annualized asthma exacerbation rate (Baseline through Week 48)Enrollment:Target 400Sites: 160RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2027AZD6793Chronic Obstructive Pulmonary Disease (COPD)NCT07082738

Phase 2Q4 2027AZD1163Rheumatoid ArthritisNCT07276581

Primary: Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12 (Week 12)Enrollment:Target 320Sites: 144RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2027AZD8359Metastatic Prostate CancerNCT07529717

Phase 3Q4 2027VolrustomigLocally Advanced Cervical CancerNCT06079671

Phase 2Q4 2027RilvegostomigGastric CancerNCT05702229

Phase 2Q4 2027Selumetinib granule formulationNeurofibromatosis Type 1NCT05309668

Phase 3Q4 2027BGF MDI 320/14.4/9.6 μgCOPD (Chronic Obstructive Pulmonary Disease)NCT06283966

Phase 2Q4 2027CamizestrantAdvanced Breast CancerNCT07427394

Phase 2Q4 2027AZD0292Bronchiectasis With Pseudomonas Aeruginosa ColonizationNCT07088926

Phase 2Q4 2027AZD5851Hepatocellular CarcinomaNCT06084884

Phase 3Q4 2027FulvestrantLocally Advanced or Metastatic Breast CancerNCT06764186

Phase 3Q1 2028SaruparibMetastatic Castration-Sensitive Prostate CancerNCT06120491

Phase 3Q1 2028Dato-DXdBreast CancerNCT07205822

Phase 2Q1 2028AZD9574Advanced Solid MalignanciesNCT05417594

Phase 2Q1 2028SurovatamigB-cell Acute Lymphoblastic Leukemia (B-ALL)NCT06137118

Phase 3Q1 2028BenralizumabEosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)NCT06512883

Phase 3Q1 2028Baxdrostat/dapagliflozinChronic Kidney Disease and HypertensionNCT06268873

Phase 2Q1 2028SurovatamigChronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell LymphomaNCT06564038

Phase 2Q1 2028AZD4512B-cell Non-Hodgkin LymphomaNCT07123454

Phase 3Q1 2028TezepelumabChronic Rhinosinusitis With Nasal PolypsNCT07520162

Phase 3Q1 2028OsimertinibNon-small Cell Lung CancerNCT06350097

Phase 2Q1 2028VolrustomigLocally Advanced Cervical CancerNCT06943833

Phase 3Q2 2028VolrustomigMetastatic Non-small Cell Lung CancerNCT05984277

Primary: Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1) (Up to approximately 6 years)Enrollment:895/895Sites: 247RANDOMIZED, TREATMENT

Phase 2Q2 2028SurovatamigPrimary Membranous NephropathyNCT07571746

Phase 2Q2 2028B-cell Acute Lymphoblastic Leukemia (B-ALL)NCT07109219

Phase 3Q2 2028TezepelumabAsthmaNCT06023589

Phase 3Q2 2028GemcitabineBiliary Tract CancerNCT06467357

Phase 3Q2 2028AZD0120Relapsed Refractory Multiple MyelomaNCT07391657

Phase 3Q3 2028ElecoglipronType 2 Diabetes MellitusNCT07662044

Phase 3Q3 2028ElecoglipronWeight ManagementNCT07667803

Phase 2Q3 2028Torvutatug samrotecanOvarian Cancer, Lung Adenocarcinoma, Endometrial CancerNCT05797168

Phase 3Q3 2028LenbelintideObesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2NCT07776509

Phase 2Q3 2028AZD8965 low doseIdiopathic Pulmonary Fibrosis (IPF)NCT07652658

Phase 3Q4 2028AnifrolumabSystemic Lupus ErythematosusNCT05835310

Primary: Part A- Anifrolumab serum concentration (Pre-dose Day 29)Enrollment:Target 100Sites: 103RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2028AZD0120Newly Diagnosed Multiple Myeloma (NDMM)NCT07735637

Phase 2Q4 2028AcalabrutinibMantle Cell Lymphoma (MCL)NCT05951959

Phase 3Q4 2028DurvalumabUrinary Bladder Neoplasms, Immune Checkpoint Inhibitors, MethotrexateNCT06960577

Phase 3Q4 2028DurvalumabCarcinoma, Non-Small-Cell LungNCT03833154

Phase 3Q4 2028VolrustomigUnresectable Pleural MesotheliomaNCT06097728

Phase 3Q4 2028AZD5335Epithelial Ovarian CancerNCT07218809

Primary: Progression free Survival (PFS) (Up to approximately 5 years)Enrollment:Target 1,100Sites: 299RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2028Dato-DXdBreast CancerNCT06112379

Phase 3Q4 2028Durvalumab + Chemotherapy phaseAdvanced or Recurrent Endometrial CancerNCT06746116

Phase 2Q4 2028VolrustomigSub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)NCT06535607

Phase 3Q4 2028Tozorakimab Dose Regimen 1Chronic Obstructive Pulmonary Disease, COPDNCT07566195

Phase 3Q1 2029RilvegostomigBiliary Tract CancerNCT06109779

Phase 2Q1 2029AZD0516Metastatic Prostate CancerNCT07181161

Phase 3Q1 2029Trastuzumab deruxtecanEndometrial CancerNCT06989112

Phase 3Q1 2029AnifrolumabSystemic Lupus ErythematosusNCT07430306

Phase 2Q1 2029AZD9750Prostate CancerNCT07336446

Phase 3Q1 2029Datopotamab deruxtecan (Dato-DXd)Non-small Cell Lung Cancer (NSCLC)NCT07291037

Primary: Progression-free survival (PFS) (Approximately 2.5 years)Enrollment:Target 400Sites: 206RANDOMIZED, TREATMENT

Phase 2Q1 2029AZD3632Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic SyndromesNCT07155226

Phase 2Q1 2029RilvegostomigAdvanced or Metastatic Non-small Cell Lung CancerNCT06996782

Phase 3Q1 2029CamizestrantER-Positive HER2-Negative Breast CancerNCT07647328

Phase 3Q1 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06883305

Phase 3Q1 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06878261

Phase 2Q1 2029AZD6621Prostate CancerNCT07192614

Phase 3Q1 2029Saruparib (AZD5305)Advanced Breast CancerNCT06380751

Phase 2Q2 2029RilvegostomigNon-Small Cell Lung CancerNCT07098338

Phase 2Q2 2029AcalabrutinibDiffuse Large B-Cell LymphomaNCT05952024

Primary: Percentage of patients with Grade 3 to 4 treatment emergent adverse events (TEAEs) (Cycle 1 Day 1 (Cycles 1 to 8 is 21 days and Cycles 9 to 28 is 28 days) through End of treatment EoT [30 days of discontinuation] (Up to 3.5 Years))Enrollment:Target 80Sites: 57NA, TREATMENT

Phase 3Q2 2029RilvegostomigHER2-positive Gastric Cancer, Gastroesophageal Junction AdenocarcinomaNCT06764875

Phase 2Q2 2029AcalabrutinibChronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)NCT07024706

Phase 2Q2 2029AZD0120Lupus Erythematosus, SystemicNCT06897930

Phase 3Q2 2029RilvegostomigNon-squamous Non-small Cell Lung CancerNCT06627647

Primary: Overall survival (OS) (Up to approximately 6 years)Enrollment:Target 1,160Sites: 300RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2029AsthmaNCT07525375

Phase 2Q2 2029OsimertinibLung CancerNCT07295821

Phase 2Q2 2029OsimertinibNon-small Cell Lung CancerNCT05546866

Phase 3Q2 2029DurvalumabSmall Cell Lung CarcinomaNCT06992609

Phase 3Q3 2029RilvegostomigBiliary Tract CancerNCT07221253

Phase 3Q3 2029Sonesitatug vedotinGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal CancerNCT07431281

Phase 2Q3 2029AZD2265 (FPI-2265)Metastatic Prostate CancerNCT07590934

Phase 2Q4 2029AZD6750Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)NCT07115043

Phase 3Q4 2029AZD0780Cardiovascular DiseaseNCT07000357

Phase 2Q4 2029Osimertinib 80 mg/40 mgStage II-IIIB Non-small Cell Lung CarcinomaNCT05526755

Phase 3Q4 2029Baxdrostat and dapagliflozinHeart FailureNCT06677060

Phase 3Q4 2029Baxdrostat/dapagliflozinChronic Kidney Disease and HypertensionNCT06742723

Phase 2Q4 2029AZD5492B-cell MalignanciesNCT06542250

Phase 3Q4 2029Datopotamab DeruxtecanNon-Small Cell Lung CancerNCT06357533

Phase 3Q4 2029BenralizumabAsthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)NCT07444567

Phase 3Q1 2030RilvegostomigCarcinoma, Non-Small Cell LungNCT06868277

Phase 3Q1 2030Sodium Zirconium Cyclosilicate (SZC) Reduced Dose LevelHyperkalaemiaNCT03813407

Phase 3Q1 2030VolrustomigAdvanced Clear Cell Renal Cell CarcinomaNCT07000149

Phase 3Q1 2030CamizestrantBreast Cancer, Early Breast CancerNCT05952557

Phase 3Q1 2030TremelimumabHepatocellular CarcinomaNCT06921785

Primary: To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCC (Up to approximately 6 years)Enrollment:Target 1,220Sites: 219RANDOMIZED, SINGLE, TREATMENT

Phase 2Q1 2030AZD4956Solid TumoursNCT07446855

Phase 3Q2 2030volrustomigLocally Advanced Head and Neck Squamous Cell CarcinomaNCT06129864

Phase 3Q2 2030BenralizumabAsthmaNCT05692180

Phase 2Q2 2030DurvalumabNon-small Cell Lung CancerNCT05061550

Phase 3Q2 2030AZD0486Large B-cell LymphomaNCT07215585

Phase 3Q3 2030RilvegostomigNon-small Cell Lung CancerNCT06692738

Phase 3Q3 2030Balcinrenone/dapagliflozinRenal Insufficiency, ChronicNCT07624305

Phase 2Q3 2030Systemic Lupus ErythematosusNCT07630714

Phase 3Q4 2030ElecoglipronChronic Kidney DiseaseNCT07753993

Phase 2Q1 2031AZD4045Relapsed or Refractory Multiple MyelomaNCT07681596

Phase 2Q2 2031AZD5305Metastatic Prostate CancerNCT05367440

Phase 3Q2 2031SaruparibMetastatic Hormone-Sensitive Prostate Cancer (m HSPC)NCT07711002

Phase 3Q3 2031SurovatamigChronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHVNCT07509151

Phase 3Q4 2031SurovatamigUntreated Follicular LymphomaNCT06549595

Phase 3Q4 2032AnifrolumabSystemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus ErythematosusNCT07691970

Phase 3Q1 2033SaruparibProstate CancerNCT06952803

ASTRAZENECA PLC

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Recent Insider Activity

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research